无症状(沉默性)脑微出血与疑似脑淀粉样血管病的心血管管理
本文综述无症状脑微出血(CMBs)和皮质表面铁沉积在一般人群、缺血性卒中患者和记忆门诊中的临床意义。新兴证据(非随机对照试验)提示,对大多数患者,当抗栓或抗凝治疗另有指征时,单纯CMBs不应阻止其用于卒中预防。作者基于有限文献和个人临床实践提出具体临床照护建议。
要点
- CMBs是脑小血管病(如散发性脑淀粉样血管病或非淀粉样小血管病理)的征象,在卒中、认知障碍和健康人群中患病率高。
- 历史上研究过度强调CMBs的未来出血风险,可能导致不必要的停用已证实有效的抗栓药物(如房颤患者的抗凝药)。
- 新兴证据(非随机对照试验)提示,对大多数患者,单纯CMBs不应阻止另有指征的抗栓或抗凝治疗用于卒中预防。
核心结论
- 新兴证据(非随机对照试验)提示,对大多数患者,单纯CMBs不应阻止另有指征的抗栓或抗凝治疗用于卒中预防。
研究设计与样本
- 本文为综述,批判性回顾和讨论无症状CMBs和皮质表面铁沉积(无症状性颅内出血)在一般人群、缺血性卒中患者和记忆门诊中的意义。
主要发现
- CMBs在卒中、认知障碍和健康人群中患病率高,部分归因于磁共振成像的广泛使用。
- CMBs与未来出血性卒中和缺血性卒中均相关,造成抗栓药物安全性的临床不确定性。
- 历史上研究文献绝大多数强调CMBs相关的未来出血风险,可能导致不必要的停用已证实有效的抗栓治疗(如房颤患者的抗凝药)。
- 该领域缺乏强有力的指南,导致临床实践差异很大。
临床怎么用
- 作者基于有限文献和个人临床实践,在可能处提供具体临床照护建议。
- 原文未据此给出推荐。
局限性
- 新兴证据并非来自随机对照试验。
- 可用的文献有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cerebral microbleeds (CMBs) detected on blood-sensitive magnetic resonance imaging sequences are usually a sign of an underlying cerebral small vessel disease such as sporadic cerebral amyloid angiopathy or sporadic nonamyloid small vessel pathology (eg, arteriolosclerosis). Much of the enduring interest in CMBs relates to their high prevalence (partly due to the widespread use of magnetic resonance imaging) in the context of stroke, cognitive impairment and in healthy individuals, and the clinical uncertainties created about the safety of antithrombotic medications due to their association with both future hemorrhagic and ischemic stroke. Historically, the research literature overwhelmingly emphasized the future hemorrhagic risk associated with CMBs, potentially leading to unnecessary withholding of treatments proven effective at preventing thrombosis, such as anticoagulants in patients with atrial fibrillation who happened to have some microbleeds. The lack of strong guidelines in this area contributes to wide variation in clinical practice. In this article, we critically review and discuss the implications of silent CMBs and cortical superficial siderosis (ie, without symptomatic intracerebral hemorrhage) in different clinical settings: the general population, patients with ischemic stroke, and the memory clinic. Emerging evidence, albeit not from randomized controlled trials, suggests that in most patients, CMBs alone should not prevent the use of antithrombotics or anticoagulants for stroke prevention, when they are otherwise indicated. Where possible, we provide specific suggestions for clinical care grounded in both the limited available literature and our personal clinical practice.
引用
- Charidimou A, Smith EE. Cardiovascular Management in Asymptomatic (Silent) Cerebral Microbleeds and Suspected Cerebral Amyloid Angiopathy. Stroke. 2024. PMID: 38465605. doi:10.1161/STROKEAHA.123.044167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。